Literature DB >> 7686916

Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.

M A Vaccarello1, F B Diamond, J Guevara-Aguirre, A L Rosenbloom, P J Fielder, S Gargosky, P Cohen, K Wilson, R G Rosenfeld.   

Abstract

Profound growth failure despite elevated GH levels in GH receptor deficiency (GHRD) results from reduced insulin-like growth factor-I (IGF-I) synthesis. Recent reports of improved growth velocity in children with GHRD during IGF-I therapy indicate growth-promoting potential in humans. We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD. Hypoglycemia (< 2.5 mmol/L) did not occur, and mean 2 h postprandial insulin levels were reduced. Urinary calcium increased 2-fold (P < 0.01), and serum calcium was unchanged. The mean integrated 24-h GH level was suppressed (6.5 +/- 2.1 to 1 +/- 0.2 micrograms/L), as were the number of peaks, area under the curve, and clonidine-stimulated GH release (all P < 0.05). The mean pretreatment IGF-I level (36 +/- 2 micrograms/L) was 19% of the Ecuadorian control value (190 +/- 15 micrograms/L), it achieved a peak (253 +/- 11 micrograms/L) between 2-6 h after IGF-I injection, and at 12 h it was 137 +/- 8 micrograms/L. There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03). Baseline IGF-II levels were 47% of the control value and decreased during IGF-I therapy (273 +/- 10 to 178 +/- 9 micrograms/L; P < 0.01), correlating inversely with IGF-I levels (r = -0.3; P < 0.001). Although IGF-binding protein-3 (IGFBP-3) levels were not significantly influenced, baseline IGFBP-2 levels (153% of the control) increased 45% (P < 0.01). We conclude that IGF-I (40 micrograms/kg every 12 h) given sc to adults with GHRD is safe; achieves normal levels of IGF-I; reduces insulin, IGF-II, and GH levels; and increases IGFBP-2 concentrations and urinary excretion of calcium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686916     DOI: 10.1210/jcem.77.1.7686916

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Familial growth hormone insensitivity syndrome.

Authors:  A H Zargar; B A Laway; S R Masoodi; M Salahuddin; M A Siddiqui
Journal:  Indian J Pediatr       Date:  1995 Mar-Apr       Impact factor: 1.967

2.  Familial growth hormone insensitivity syndrome.

Authors:  A H Zargar; B A Laway; S R Masoodi; M Salahuddin; M A Siddiqui
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

Review 3.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

Review 4.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

Review 5.  IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action?

Authors:  G P Ceda
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

Review 6.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

7.  Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children.

Authors:  Robert J Ferry; Pinchas Cohen; Lorraine E Levitt Katz
Journal:  Horm Res       Date:  2005-05-09

8.  Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).

Authors:  K Hanew; A Tanaka
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

9.  Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly.

Authors:  Peter Kamenicky; Say Viengchareun; Anne Blanchard; Geri Meduri; Philippe Zizzari; Martine Imbert-Teboul; Alain Doucet; Philippe Chanson; Marc Lombès
Journal:  Endocrinology       Date:  2008-04-03       Impact factor: 4.736

10.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.